Intravenous lacosamide for treatment of status epilepticus
Article first published online: 26 SEP 2010
© 2010 John Wiley & Sons A/S
Acta Neurologica Scandinavica
Volume 123, Issue 2, pages 137–141, February 2011
How to Cite
Kellinghaus, C., Berning, S., Immisch, I., Larch, J., Rosenow, F., Rossetti, A. O., Tilz, C. and Trinka, E. (2011), Intravenous lacosamide for treatment of status epilepticus. Acta Neurologica Scandinavica, 123: 137–141. doi: 10.1111/j.1600-0404.2010.01423.x
- Issue published online: 4 JAN 2011
- Article first published online: 26 SEP 2010
- Accepted for publication July 27, 2010
- status epilepticus;
Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Rossetti AO, Tilz C, Trinka E. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand: 2011: 123: 137–141. © 2010 John Wiley & Sons A/S.
Objectives – Treatment of established status epilepticus (SE) requires immediate intravenous anticonvulsant therapy. Currently used first-line drugs may cause potentially hazardous side effects. We aimed to assess the efficacy and safety of intravenous lacosamide (LCM) in SE after failure of standard treatment.
Methods – We retrospectively analyzed 39 patients (21 women, 18 men, median age 62 years) from the hospital databases of five neurological departments in Germany, Austria and Switzerland between September 2008 and January 2010 who were admitted in SE and received at least one dose of intravenous LCM.
Results – Types of SE were generalized convulsive (n = 6), complex partial (n = 17) and simple partial (n = 16). LCM was administered after failure of benzodiazepins or other standard drugs in all but one case. Median bolus dose of LCM was 400 mg (range 200–400 mg), which was administered at 40–80 mg/min in those patients where infusion rate was documented. SE stopped after LCM in 17 patients, while 22 patients needed further anticonvulsant treatment. The success rate in patients receiving LCM as first or second drug was 3/5, as third drug 11/19, and as fourth or later drug 3/15. In five subjects, SE could not be terminated at all. No serious adverse events attributed to LCM were documented.
Conclusions – Intravenous LCM may be an alternative treatment for established SE after failure of standard therapy, or when standard agents are considered unsuitable.